Using quantification of the PML-RARα transcript to stratify the risk of relapse in patients with acute promyelocytic leukemia

Haematologica

Volumn 92, Issue 3, 2007, Pages 315-322

  Santamaría, Carlos ^a   Chillón, Maria Carmen ^a   Fernández, Carina ^a   Martín Jiménez, Patricia ^a   Balanzategui, Ana ^a   Sanz, Ramón García ^a   San Miguel, Jesús F ^a   González, Marcos Gonzalez ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Acute promyelocytic leukemia; Minimal residual disease; RQ PCR

Indexed keywords

IDARUBICIN; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; PROMYELOCYTIC LEUKEMIA PROTEIN; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; AIDA PROTOCOL; ANTINEOPLASTIC AGENT; COMPLEMENTARY DNA; MESSENGER RNA; ONCOPROTEIN; PROMYELOCYTIC LEUKEMIA RETINOIC ACID RECEPTOR ALPHA FUSION ONCOPROTEIN; PROMYELOCYTIC LEUKEMIA-RETINOIC ACID RECEPTOR ALPHA FUSION ONCOPROTEIN; RNA; TUMOR MARKER; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; FUSION GENE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC TRANSCRIPTION; HUMAN; INTERMETHOD COMPARISON; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROMYELOCYTIC LEUKEMIA; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SCHOOL CHILD; SURVIVAL RATE; SURVIVAL TIME; BLOOD; CHILD; CLINICAL TRIAL; COMPUTER SYSTEM; DRUG MONITORING; GENE DOSAGE; GENETICS; KAPLAN MEIER METHOD; LEUKOCYTE COUNT; METHODOLOGY; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY; POLYMERASE CHAIN REACTION; PREDICTION AND FORECASTING; RECURRENT DISEASE; REMISSION; SALVAGE THERAPY; SENSITIVITY AND SPECIFICITY; STATISTICS; SURVIVAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CLINICAL TRIALS; COMPUTER SYSTEMS; DISEASE-FREE SURVIVAL; DNA, COMPLEMENTARY; DRUG MONITORING; FEMALE; FOLLOW-UP STUDIES; GENE DOSAGE; HUMANS; IDARUBICIN; KAPLAN-MEIERS ESTIMATE; LEUKEMIA, PROMYELOCYTIC, ACUTE; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MULTICENTER STUDIES; NEOPLASM, RESIDUAL; ONCOGENE PROTEINS, FUSION; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; RECURRENCE; REMISSION INDUCTION; RISK ASSESSMENT; RNA, MESSENGER; RNA, NEOPLASM; SALVAGE THERAPY; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TRETINOIN; TUMOR MARKERS, BIOLOGICAL;

EID: 34247607823     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.10734     Document Type: Article

References (35)

1. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Woods WG, et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 2002;100:4298-302.
2. Sanz MA, Martín G, Rayón C, Estevez J, González M, Díaz-Mediavilla J, et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARα positive acute promyelocytic leukemia. Blood 1999;94:3015-21.
3. Lo Coco F, Diverio D, Falini B, Biondi A, Nervi C, Pelicci PG. Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. Blood 1999;94:12-22.
4. Burnett AK, Grimwade D, Solomon E, Wheadey K, Goldstone AH. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the randomized MRC trial. Blood 1999;93: 4131-3.
5. Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E, et al. A randomized comparison of all trans retinoic acid (ATRA) followed by chemotherapy and ATPA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood 1999;94: 1192-200.
6. Sanz MA, Lo Coco F, Martín G, Avvisati G, Rayón C, Barbui T, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000; 96: 1247-53.
7. Breccia M, Diverio D, Noguera NI, Visan G, Santero A, Locatelli F, et al. Clinico-biological features and outcome of acute promyelocytic leukemia patients with persistent polymerase chain reaction-detectable disease after the AIDA front-line induction and consolidation therapy. Haematologica 2004;89:29-33.
8. Tobal K, H Moore H, M Macheta M, Liu Yin JA. Monitoring minimal residual disease and predicting relapse in APL by quantitating PML-RARα transcripts with a sensitive competitive RT-PCR method. Leukemia 2001;15:1060-5.
9. Jurcic JG, Nimer SD, Scheinberg DA, DeBlasio T, Warrell RP Jr, Miller WH Jr. Prognostic significance of minimal residual disease detection and PML/RARα isoform type: long-term follow-up in acute promyelocytic leukemia. Blood 2001;98:2651-6.
10. Sanz MA, Tallman MS, Lo Coco F. Tricks of the trade for the appropriate management of newly diagnosed acute promyelocytic leukemia. Blood 2005;105:3019-25.
11. Diverio D, Rossi V, Avvisati G, De Santis S, Pistilli A, Pane F, et al. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML-RARα fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. GIMEMA-AIEOP Multicenter "AIDA" Trial. Blood 1998;92:784-9.
12. Mandelli F, Diverio D, Avvisati G, Luciano A, Barbui T, Bernasconi C, et al. Molecular remission in PML/ RARα-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood 1997; 90:1014-21.
13. Grimwade D, Lo Coco F. Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia. Leukemia 2002;16:1959-73.
14. Gameiro P ,Vieira S, Carrara P, Silva AL, Diamond J, De Sousa B, et al. The PML-RARα transcript in long-term follow-up of acute promyelocytic leukemia patients. Haematologica 2001;86:577-85.
15. Bolufer P, Lo Coco F, Grimwade D, Barragán E, Diverio D, Cassinat B, et al. Variability in the levels of PML-RARα fusion transcripts detected by laboratories participating in an external quality control program using several reverse transcription polymerase chain reaction protocols. Haematologica 2001;86:570-6.
16. Gabert J, Beillard E, van der Velden VHJ, Grimwade D, Pallisgaard N, Garbany G, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 2003;12:2318-57.
17. Cassinat B, Zassadowski F, Balitrand N, Barbey C, Rain JD, Fenaux P, et al. Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR. Leukemia 2000; 14: 324-8.
18. Slack JL, Bi W, Livak KJ, Beaubier N, Yu M, Clark M, et al. Pre-clinical validation of a novel, highly sensitive assay to detect PML-RARα using real-time reverse-transcription polymerase chain reaction. J Mol Diagn 2001;3:141-9.
19. Gallagher RE, Yeap BY, Bi W, Livak KJ, Beaubier N, Rao S, et al. Quantitative real-time RT-PCR analysis of PML-RARα mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129. Blood 2003; 101:2521-8.
20. Gallagher RE, Schachter-Tokarz E, Liao K, Jones D, Estey E. MRD monitoring in acute promyelocytic leukemia: unresolved issues in 2005. Haematologica Reports 2005;1:76-9.
21. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985;103:620-5.
22. van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999;13:1901-28.
23. Sanz M, Martin G, Gonzalez M, Leon A, Rayon C, Rivas C, et al. Risk adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 2004;103:1237-43.
24. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162:156-9.
25. Gonzalez M, Barragan E, Bolufer P, Chillon C, Colomer D, Borstein R, et al. Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to the PML-RAR alpha isoforms: a study of the PETHEMA group. Br J Haematol 2001;114:99-103.
26. Beillard E, Pallisgaard N, van der Velden VHJ, Bi W, Dee R, van der Schoot E, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe Against Cancer program. Leukemia 2003;12:2474-86.
27. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457.
28. Cox DR. Regression models and life tables. J R Stat Soc B 1972;34:187-220.
29. Schnittger S, Weisser M, Schoch C, Hiddemann W, Haferlach T, Kern W. New score predicting for prognosis in PML-RARα, AML1-ETO, or CBFB-MYH11 acute myeloid leukemia based on quantification of fusion transcripts. Blood 2003;102:2746-55.
30. Lee S, Kim YJ, Eom KS, Min CK, Kim HJ, Cho SG, et al. The significance of minimal residual disease kinetics in adults with newly diagnosed PML-RAR alpha-positive acute promyelocytic leukemia: results of a prospective trial. Haematologica 2006;91:671-4.
31. Pane F, Cimino G, Izzo B, Camera A, Vitale A, Quintarelli C, et al. Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia. Leukemia 2005;19:628-35.
32. Tobal K, Newton J, Macheta M, Chang J, Morgenstern G, Evans PA, et al. Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse. Blood 2000;95:815-9.
33. Zhu J, Lallemand-Breitenbach V, de The H. Pathways of retinoic acid- or arsenic trioxide-induced PML/ RARα catabolism, role of oncogene degradation in disease remission. Oncogene 2001;20:7257-65.
34. Cassinat B, De Botton S, Ades L, Raffoux E, Escoffre-Barbe M, Baruchel A, et al. Assessment of PML-RARα real-time quantitative PCR for definition of molecular relapse in APL patients (results of the APL Study Group). Blood (ASH Annual Meeting Abstracts) 2005;106: [abstract 672].
35. Liu YF, Zhu YM, Shen SH, Shen ZX, Li JM, Chen SJ, et al. Molecular response in acute promyelocytic leukemia: a direct comparison of regular and real-time RT-PCR. Leukemia 2006;20:1393-9.